Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional cemiplimab in adult patients with cutaneous squamous cell carcinoma or basal cell carcinoma
NL-OMON59047Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary endpoint(s). Started Mar 2025; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON59047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59047.